866-997-4948(US-Canada Toll Free)

Viral Vector and Plasmid DNA: Technologies and Global Markets

Published By :

BCC Research

Published Date : Sep 2019

Category :

Biotechnology

No. of Pages : 133 Pages

"Summary

Viral vectors are viruses developed through cultured DNA recombination techniques. This modification makes the viruses ideal for delivering genetic material into target cells or tissues for therapeutic purposes. Types of viral vectors include adenoviruses, retroviruses, poxviruses, adeno-associated viruses (AAV), and herpes simplex viruses (HSVs). Delivery of foreign DNA using viral vectors has flaws, particularly when attempts are made to apply the technology to gene therapy. However, as researchers learn more about viral vectors and their impact on human immune response, advancements in safe and effective viral-based treatments continue. Meanwhile, the refinement of viral-mediated gene delivery
protocols proceeds, providing a convenient, flexible, and reproducible system for in vitro transfection studies. Plasmid DNA vaccines offer speed, simplicity, and breadth of immune response by overcoming the issues regarding effectiveness and safety of therapy during treatment. Innovative plasmid DNA vaccines can be useful for the immunization of humans against infectious diseases and cancers.

The global viral vector and plasmid DNA technologies market is estimated to grow significantly, reaching a compound annual growth rate (CAGR) of REDACTED during the forecast period, 2019-2024. The global viral vector and plasmid DNA technologies market was valued at REDACTED in 2018 and is projected to exceed REDACTED by 2024. The markets projected growth stems from factors such as the rising prevalence of various diseases such as cancer, infectious diseases, and other genetic disorders, the growing trend toward gene therapy owing to their promising clinical results, and increasing partnerships and collaborations between companies and research institutes in gene therapy.

The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market. According to the WHO (World Health Organization), cancer is the second-leading cause of mortality in the world, responsible for 9.6 million deaths and accounting for 18.1 million new cases in 2018. Consequently, there is significant demand for cancer therapeutics based on innovative technologies such as viral vectors and plasmid DNA. Viral vectors are being researched for applications in cancer therapies and to support the delivery of genetic information to a tumor, which will permit the development of therapeutic proteins. The process typically involves introducing DNA into a cell (transfection), which encodes for a protein and other important genetic elements needed for the introduction of the gene of interest expression that facilitates successful production of protein. Some approved gene therapies, like Kymriah for acute lymphoblastic leukemia (ALL) and large B cell lymphoma, have induced market players to research and develop of gene therapy for cancer treatment. However, regulatory challenges, vector characterization and QC testing, and manufacturing challenges have restrained growth in the global viral vector and plasmid DNA technologies market.

The global viral vector and plasmid DNA technologies market was segmented based on product, application and end-user. Based on product, the global viral vector and plasmid DNA technologies market further is analyzed into plasmid DNA and viral vectors. Among products, the viral vector segment held the largest share in the viral vector and plasmid DNA technologies market with a value of REDACTED in 2018. The market is projected to reach REDACTED by 2024, growing at a CAGR of REDACTED during the forecast period. The viral vector is the most operative resource of gene transfer to modify specific cell type or tissue and can be manipulated to express therapeutic genes. Various types of viruses include adenoviruses, retroviruses (-retroviruses and lentiviruses), poxviruses, AAV, baculoviruses and HSV. These viruses are under investigation as applications to deliver genes to cells for either transient or permanent transgene expression. The rising applications of these viruses should boost growth of the viral vector in gene therapy."

"Report Scope:

The report provides a comprehensive summary of the viral vector and plasmid DNA technologies market, along with detailed profiles of key market players that includes revenue product portfolio and recent activities. The report analyzes trends and dynamics, including drivers, limitations and challenges and opportunities. The report discusses strategies adopted by emerging market players with recommendations for the new market entrants. This research study discusses historical, current, and potential market size. The report will enable market players and new entrants to make informed decisions about the production and exports of the goods and services to the original equipment manufacturer. Organizations, distributors and exporters should find the information about market development and trends useful.

The study segments the market on the basis of product type, applications and end-use. Geographical market analysis is provided for all the major segments. The report offers country level analysis of markets to provide better understanding of the major segments.

Report Includes:

- 44 data tables and 14 additional tables
- An in-depth assessment of the global viral vector and plasmid DNA technologies market within the life sciences sectors
- Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
- The latest information on key technical advances in different viral vector and plasmid DNA technologies, and the extent of adoption by commercial customers and regulatory authorities
- A proprietary analysis of the market including an easy-to-understand graphical representation of facts, innovations in pharmaceutical and biotechnology companies, and R&D activities in viral vector-based treatments and Plasmid DNA vaccines
- Key strategies adopted by major players in the market and the impact of new technological developments in developed and emerging markets
- Assessment of the suppliers landscape on the basis of companies best positioned to meet this ever evolving demand
- Comprehensive company profiles of market leading players, including Aldevron LLC, Merck KGaA, Lonza Group Ltd., GenScript Biotech Corp., Pfizer Inc., and Thermo Fisher Scientific, Inc."
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Gene Therapy
Plasmid Production
Description of Market Trends
Market Dynamics
Chapter 4 Market Breakdown by Product Type
Plasmid DNA
Viral Vector
Chapter 5 Market Breakdown by End User
Research Institutes
Pharmaceutical and Biopharmaceutical Companies
Chapter 6 Market Breakdown by Application
Cancer
Infectious Diseases
CVD
Other Applications
Chapter 7 Market Breakdown by Region
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Middle East and Africa (MEA)
Latin America
Chapter 8 Patent Review/New Developments
New Products and Technologies
Patent Analysis
Chapter 9 Analysis of Market Opportunities
Key Suppliers and Manufacturers: Positioning and Strategy
Thermo Fisher Scientific, Inc.
Merck KGaA
Lonza Group Ltd.
GenScript Biotech Corp.
Pfizer Inc.
R&D Programs
Pipeline Analysis
Discovery
Chapter 10 Company Profiles
ABEONA THERAPEUTICS INC.
AKRON BIOTECH
ALDEVRON, LLC
AMARNA THERAPEUTICS B.V.
APPLIED BIOLOGICAL MATERIALS INC.
AUDENTES THERAPEUTICS INC.
BATAVIA BIOSCIENCES B.V.
BAYER AG
BIOMARIN PHARMACEUTICAL INC.
BIONTECH IMFS GMBH
BLUEBIRD BIO INC.
CELLECTA INC.
COBRA BIOLOGICS LTD.
CRISPR THERAPEUTICS AG
DELPHI GENETICS S.A.
FINVECTOR VISION THERAPIES OY
FUJIFILM DIOSYNTH BIOTECHNOLOGIES INC.
GENSCRIPT BIOTECH CORP.
GENEZEN LABORATORIES
GENERAL ELECTRIC CO.
IMMUSOFT CORP.
LAKEPHARMA INC.
LONZA GROUP LTD.
LYSOGENE SA
MAXCYTE INC.
MERCK KGAA
NOVARTIS INTERNATIONAL AG
NOVASEP HOLDING SAS
ORCHARD THERAPEUTICS PLC
ORIGENE TECHNOLOGIES INC.
OXFORD BIOMEDICA PLC
OXFORD GENETICS LTD.
PFIZER INC.
PLASMIDFACTORY GMBH & CO. KG
POSEIDA THERAPEUTICS INC.
PROMEGA CORP.
PSIOXUS THERAPEUTICS LTD.
REGENXBIO INC.
REPLIGEN CORP.
ROCKET PHARMACEUTICALS, LTD.
SANGAMO THERAPEUTICS INC.
SIRION-BIOTECH GMBH
SIGNAGEN LABORATORIES
SPARK THERAPEUTICS INC.
THERMO FISHER SCIENTIFIC, INC.
ULTRAGENYX PHARMACEUTICAL INC.
UNIQURE N.V.
VGXI INC.
VIGENE BIOSCIENCES INC.
WAISMAN BIOMANUFACTURING
YPOSKESI INC.

List of Table

List of Tables
Summary Table : Global Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
Table 1 : Types of Gene Therapy
Table 2 : Clinical Trials for Viral Vector-Mediated Gene Therapy in the U.S., 2018 and 2019
Table 3 : Partnerships for Viral Vector-Mediated Gene Therapy
Table 4 : Global Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
Table 5 : Characteristics of Plasmid DNA Isolation Technology, 2019
Table 6 : Global Market for Plasmid DNA, by Region, Through 2024
Table 7 : Global Market for Viral Vector, by Region, Through 2024
Table 8 : Global Market for Viral Vector and Plasmid DNA, by End User, Through 2024
Table 9 : Global Market for Viral Vector and Plasmid DNA in Research Institutes, by Region, Through 2024
Table 10 : Global Market for Viral Vector and Plasmid DNA in Pharmaceutical and Biopharmaceutical Companies, by Region, Through 2024
Table 11 : Global Market for Viral Vector and Plasmid DNA, by Application, Through 2024
Table 12 : Viral Vectors Used in Gene Therapy
Table 13 : Global Market Viral Vector and Plasmid DNA in Cancer, by Region, Through 2024
Table 14 : Pipeline Products for Cancer Gene Therapy, 2018 and 2019
Table 15 : Global Market for Viral Vector and Plasmid DNA in Infectious Diseases, by Region, Through 2024
Table 16 : Gene Transfer Vectors Used in Heart Gene Therapy
Table 17 : Global Market for Viral Vector and Plasmid DNA in CVD, by Region, Through 2024
Table 18 : Global Market for Viral Vector and Plasmid DNA in Other Applications, by Region, Through 2024
Table 19 : Global Market for Viral Vector and Plasmid DNA, by Region, Through 2024
Table 20 : New Cases of Tuberculosis, by Country, 2017
Table 21 : Ebola Virus Disease Outbreaks in Chronological Order, 2012-2019
Table 22 : North American Market for Viral Vector and Plasmid DNA, by Country, Through 2024
Table 23 : North American Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
Table 24 : North American Market for Viral Vector and Plasmid DNA, by Application, Through 2024
Table 25 : North American Market for Viral Vector and Plasmid DNA, by End User, Through 2024
Table 26 : Research Institutes for Gene Therapy in the U.S.
Table 27 : New Cancer Cases in the U.S., by Gender, 2019
Table 28 : New Cancer Cases Diagnosed in Canada, 2019
Table 29 : European Market for Viral Vector and Plasmid DNA, by Country, Through 2024
Table 30 : European Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
Table 31 : European Market for Viral Vector and Plasmid DNA, by Application, Through 2024
Table 32 : European Market for Viral Vector and Plasmid DNA, by End User, Through 2024
Table 33 : New Cancer Cases and Mortalities in France, 2018
Table 34 : New Cancer Cases in European Countries, 2018
Table 35 : Asia-Pacific Market for Viral Vector and Plasmid DNA, by Country, Through 2024
Table 36 : Asia-Pacific Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
Table 37 : Asia-Pacific Market for Viral Vector and Plasmid DNA, by Application, Through 2024
Table 38 : Asia-Pacific Market for Viral Vector and Plasmid DNA, by End User, Through 2024
Table 39 : New Cancer Cases and Mortalities in China, 2018
Table 40 : New Cancer Cases in Asia-Pacific Countries, 2018
Table 41 : MEA Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
Table 42 : MEA Market for Viral Vector and Plasmid DNA, by Application, Through 2024
Table 43 : MEA Market for Viral Vector and Plasmid DNA, by End User, Through 2024
Table 44 : Latin American Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
Table 45 : Latin American Market for Viral Vector and Plasmid DNA, by Application, Through 2024
Table 46 : Latin American Market for Viral Vector and Plasmid DNA, by End User, Through 2024
Table 47 : New Product Developments, 2017-2019
Table 48 : Number of Patents Grants, by Categories in Different Countries, January 2017-July 2019
Table 49 : Number of Patents, by Key Players in the U.S., Europe and Japan, January 2017-July 2019
Table 50 : Total Number of Analyzed Patents, January 2017-July 2019
Table 51 : Key Financial Statistics of Thermo Fisher Scientific, Inc., 2017 and 2018
Table 52 : Key Financial Statistics of Merck KGaA, 2017 and 2018
Table 53 : Key Financial Statistics of Lonza Group Ltd., 2017 and 2018
Table 54 : Key Financial Statistics of GenScript Biotech Corp., 2017 and 2018
Table 55 : Key Financial Statistics of Pfizer Inc., 2017 and 2018
Table 56 : Viral Vector-Mediated Gene Therapies in Development, 2018 and 2019
Table 57 : Viral Vector-Mediated Gene Therapy Clinical Trials Database, 2018

List of Chart

List of Figures
Summary Figure : Global Market for Viral Vector and Plasmid DNA, by Product Type, 2018-2024
Figure 1 : Processes of Gene Therapy Research
Figure 2 : Processes of Gene Therapy Development
Figure 3 : Typical Production Process Flow for Viral Vectors
Figure 4 : Most Common Cancer Types, Global Cases, 2018
Figure 5 : Progression of cGMP Compliance for Drug Development
Figure 6 : Shares of New Cancer Cases, Globally, by Cancer Type, 2018
Figure 7 : Shares of New Cancer Cases in North America, by Cancer Type, 2018
Figure 8 : Shares of New Cancer Cases in Europe, by Cancer Type, 2018
Figure 9 : Prevalence of Cancer in U.K., 2011-2017
Figure 10 : Prevalence of Cancer in Germany, by Cancer Type, 2014-2016
Figure 11 : Colorectal Cancer Incidences in Italy, 2015 and 2016
Figure 12 : Prevalence of Colorectal Cancer in Spain, 2011-2016
Figure 13 : Shares of New Cancer Cases in Asia, by Cancer Type, 2018
Figure 14 : Shares of New Cancer Cases in Oceania, by Cancer Type, 2018
Figure 15 : Shares of New Cancer Cases in Japan, by Cancer Type, 2018
Figure 16 : Shares of New Cancer Cases in India, by Cancer Type, 2018
Figure 17 : Pharmaceutical Expenditures per Capita, by Country, 2015
Figure 18 : Shares of New Cancer Cases in MEA, by Cancer Type, 2018
Figure 19 : New HIV Cases and Mortalities in MEA, 2017
Figure 20 : Shares of New Cancer Cases in Latin America and the Caribbean, by Cancer Type, 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *